We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Cystic fibrosis programs

CF is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide and approximately 30,000 patients in the United States. CF is a chronic disease that affects the lungs and digestive system. CF patients, with significantly impaired quality of life, have an average lifespan approximately 50% shorter than the population average, with the median age of death at 40. There currently is no cure for CF. CF patients require lifelong treatment with multiple daily medications, frequent hospitalizations and ultimately lung transplant, which is life-extending but not curative. CF is caused by a mutation in the gene for the CFTR protein, which results in abnormal transport of chloride across cell membranes. Transport of chloride is required for effective hydration of epithelial surfaces in many organs of the body. Normal CFTR channel moves chloride ions to outside of the cell. Mutant CFTR channel does not move chloride ions, causing sticky mucous to build up on the outside of the cell. CFTR dysfunction results in dehydration of dependent epithelial surfaces, leading to damage of the affected tissues and subsequent disease, such as lung disease, malabsorption in the intestinal tract and pancreatic insufficiency. 

Galapagos and AbbVie entered into a global alliance to discover, develop and commercialize novel therapies in cystic fibrosis (CF) in September 2013. Galapagos and AbbVie aim to develop a triple CFTR combination therapy to address 90% of patients with CF. In order to bring a more effective therapy to patients, the companies have developed multiple candidates and backups for each of the three components of a potential triple combination. Triple combinations of CF compounds in the portfolio have consistently shown restoration of healthy activity levels in in vitro assays with human bronchial epithelial (HBE) cells of patients with the F508del mutation. These combinations result in a statistically significant increase in chloride transport over Orkambi[1] in HBE cells with the homozygous F508del mutation. In April 2018, Galapagos has announced the initiation of its first clinical trial with an investigational triple combination therapy in cystic fibrosis patients.

[1] Orkambi® is a prescription medicine sold by Vertex Pharmaceuticals, used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. 

Related publications

ECFS, June 2018

Phase 2a (ALBATROSS) - ‘2222 in subjects with CF (ClassIII/F508del) on stable treatment with Ivacaftor

Development of CFTR triple combination therapy

NACFC 2017

NACFC investor meeting 
Katja Conrath, Therapeutic Head CF and Piet Wigerinck, CSO,  2 November at The Conrad, Indianapolis

Safety, Tolerability and Pharmacokinetics of single and multiple doses of GLPG2737, a novel CFTR corrector molecule, in healthy volunteers

Pharmacokinetics and safety of a novel CFTR corrector molecule GLPG2222 in Healthy Subjects and in Subjects with Cystic Fibrosis (CF): results from two Phase I Studies

Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG2451 with and without a novel CFTR corrector GLPG2222 in healthy volunteers

Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG3067 in healthy volunteers

ECFS, June 2017

GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)

ECFS, June 2017

Discovery of ABBV/GLPG-2222, a potent CFTR corrector for the treatment of Cystic Fibrosis

ACS Meeting, April 2017

Discovery of Highly Efficacious Potentiators for the Treatment of Cystic Fibrosis

ACS Meeting, April 2017

SAPHIRA 1 topline results webcast

NACFC 2016

On track to a triple combo therapy
Slide deck investor get-together, 27 October at the Rozen Plaza, Orlando

Characterization of a novel potentiator series for treating Cystic Fibrosis

Safety, Tolerability and Pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers

The C.1766+1G a splice site mutation causes exon 13 skipping resulting in multiple defects in CFTR structure and function

Measuring potentiator activity using organoids

Characterization of novel potentiators

Novel Correctors and Potentiators Augment Efficacy of Translational Readthrough in CFTR Nonsense Mutations

GLPG1837 in subjects with cystic fibrosis and the S1251N mutation: results from a Phase 2a study (SAPHIRA2)

Other publications

Dr Katja Conrath on Galapagos' CF program at UK CF Conference 
Nottingham, 8 September 2016

Novel Potentiators Augment Efficacy of Translational Readthrough in CFTR Nonsense Mutations
NACFC 2015

Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837 in healthy volunteers
NACFC 2015

Using BLISS analysis to categorize corrector-corrector interactions
NACFC 2015

Insight into the mechanisms of correctors and potentiators
NACFC 2015

Potentiators: how do they impact the fate of CFTR during biogenesis?
NACFC 2015

Screening for corrector - potentiator combinations
Corina Balut, et al
ECFC 2015

The way forward in drug testing is mutation specific
Katja Conrath
ECFC 2014

Novel corrector-potentiator combinations for treating Cystic Fibrosis
Katja Conrath, et al
NACFC 2014

Presentation at Wells Fargo CF Seminar 2014
Piet Wigerinck

Novel potentiators for treating Cystic Fibrosis
Katja Conrath, et al
NACFC 2013